Straits Times Index
3,301.08 +4.19 (+0.13%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,476.42 +269.29 (+1.48%) FTSE 100
8,197.97 +25.82 (+0.32%) Bitcoin USD
59,350.01 +1,688.41 (+2.93%) CMC Crypto 200
1,295.50 +18.53 (+1.45%)
Ocugen, Inc. (OCGN)
After hours:
| Previous close | 1.3900 |
| Open | 1.4057 |
| Bid | 1.3200 x 3400 |
| Ask | 1.3500 x 4900 |
| Day's range | 1.3200 - 1.4100 |
| 52-week range | 0.3450 - 2.1050 |
| Volume | |
| Avg. volume | 9,819,339 |
| Market cap | 339.673M |
| Beta (5Y monthly) | 3.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the Retina World Congress (RWC) being held May 9-12, 2024 in Ft. Lauderdale, FL. “This is a terrific opportunity to share the most recent developments in mo
- GlobeNewswire
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal
- GlobeNewswire
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial),
